MAPT and Alzheimer disease: In conclusion, we have demonstrated that 9‐MF significantly prevented cognitive impairments, Aβ‐associated microglial over‐activation, and tau‐associated synaptic damage via cell‐specific inhibition of ROCK2 and GSK3β in APP/PS1 transgenic mice, providing an example of how multiple anti‐AD targets for a certain candidate were identified.